Novo - Wegovy Sales Could Now be $5bn in 2023 (BUY, TP DKK 1100, 8 pgs)
As we get clarity on the trajectory of Wegovy scrips, we are increasingly confident that both consensus & most likely the company’s own forecasts for Wegovy sales in 2023 are too low. Our model now calculates that sales could be $5bn in the US alone this year, even with a rapid fall in new patient starts. As a result, we believe that a guidance upgrade at Q1 results on May 4th is now likely. The latest scrip data shows new patient starts are peaking, which could imply that Novo have managed to take a significant part of the bolus and beaten Mounjaro to it. Within a few weeks, our model should also enable us to ascertain how many patients are discontinuing treatment, which will be a very helpful datapoint.For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.